An Observational Study of Patients With Malignant Lymphomas Treated With MabThera® SC in Everyday Clinical Practice
Conditions
Lymphoma, B-Cell, Lymphoma, Follicular
Conditions: official terms
Lymphoma, B-Cell - Lymphoma, Follicular
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Cohort, Time Perspective: Prospective
Overall Status
Recruiting
Summary
This observational study aims to assess the therapeutic responsiveness of MabThera SC in patients with malignant lymphomas under everyday clinical practice conditions. Patients with previously untreated CD-20 positive follicular non-Hodgkin's lymphoma (NHL) or previously untreated CD-20 positive diffuse large B-cell lymphoma (DLBCL) who are planned for therapy with MabThera SC according to the assessment of the physician will be prospectively enrolled for observation. No study specific measures are required; treatment and documentation will be performed according to usual clinical practice.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Women and men aged >=18 years

- Previously untreated CD-20 positive follicular NHL

- Previously untreated CD-20 positive DLBCL

- Planned therapy with MabThera SC according to the assessment of the physician (before the start and independent from this study)

- Suitability for the therapy with MabThera SC

Exclusion Criteria:

All contraindications, interactions and incompatibilities for therapy with MabThera SC
Location
Villingen-Schwenningen, Germany
Status: Recruiting
Start Date
July 2014
Completion Date
December 2018
Sponsors
Hoffmann-La Roche
Source
Hoffmann-La Roche
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page